Safety and Effectiveness of Left Bundle Branch Pacing in Patients With Cardiac Dysfunction and AV Block

NCT ID: NCT05553626

Last Updated: 2022-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-30

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter, prospective, randomized study to assess if cardiac dysfunction patients with LVEF \<50% and the estimated ventricular pacing percentage \>40% with LBBP have the non-inferior safety and efficacy than CRT on patients' cardiac function and prognosis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who meet the inclusion and exclusion criteria will be enrolled into the study. In the study, patients with cardiac dysfunction who met the enrollment criteria and will agree to participate in this trial will be 1:1 randomized to the LBBP group and the CRT group. Patients who were successfully implanted were enrolled for evaluation and follow-up. The primary end points of the study is the change of LVEF within 12 months post-implant in both LBBP Treatment Group and CRT Treatment Group

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrioventricular Block, Second and Third Degree Heart Failure Left Bundle Branch Pacing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LBBP Treatment

Patients were performed left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device

Group Type EXPERIMENTAL

Left bundle branch pacing

Intervention Type DEVICE

Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region

Bi-ventricular pacing

Intervention Type DEVICE

Bi-ventricular pacing by a CRT/CRTD device

BVP Treatment

Patients were performed bi-ventricular pacing by a CRT/CRTD device

Group Type ACTIVE_COMPARATOR

Left bundle branch pacing

Intervention Type DEVICE

Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region

Bi-ventricular pacing

Intervention Type DEVICE

Bi-ventricular pacing by a CRT/CRTD device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Left bundle branch pacing

Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region

Intervention Type DEVICE

Bi-ventricular pacing

Bi-ventricular pacing by a CRT/CRTD device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Above 18 years old
* Agree to participate in trial and sign informed consent
* NYHA cardiac function class I-III
* LVEF\<50%
* Second or complete atrioventricular block with pacing indication or ventricular pacing dependent with ventricular pacing percentage \>40%
* Patients who are willing to take the de-novo implant or device replacement or upgrade.

Exclusion Criteria

* Life expectancy \<1 year
* Patients with severe tricuspid valvular disease1 or who have undergone mechanical valve or bioprosthetic valve surgery
* Acute myocardial infarction within 1 month
* Women of childbearing age who are pregnant or becoming pregnant during the study period
* Severe liver and kidney dysfunction2
* Have been enrolled in another clinical studies that may interferes with the current trial objectives
* Evidence of severe pulmonary hypertension (PASP\>70mmHg)
* Evidence of hypertrophic cardiomyopathy which shall affect the prognosis of patients.
* The investigator believes that subject's physical condition is not suitable for participation in the trial
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

Sponsor Role collaborator

Sir Run Run Shaw Hospital

OTHER

Sponsor Role collaborator

The First Affiliated Hospital of Dalian Medical University

OTHER

Sponsor Role collaborator

Shanxi Cardiovascular Hospital

OTHER

Sponsor Role collaborator

Shanghai 10th People's Hospital

OTHER

Sponsor Role collaborator

The Second Affiliated Hospital of Harbin Medical University

OTHER

Sponsor Role collaborator

The First People's Hospital of Yunnan

OTHER

Sponsor Role collaborator

Shanghai Zhongshan Hospital

OTHER

Sponsor Role collaborator

Shenzhen Sun Yat-sen Cardiovascular Hospital

OTHER

Sponsor Role collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

Sponsor Role collaborator

Second Affiliated Hospital of Nanchang University

OTHER

Sponsor Role collaborator

Tianjin Chest Hospital

OTHER

Sponsor Role collaborator

Xiamen Cardiovascular Hospital, Xiamen University

OTHER

Sponsor Role collaborator

Yan'an Affiliated Hospital of Kunming Medical University

OTHER

Sponsor Role collaborator

Shanghai Chest Hospital

OTHER

Sponsor Role collaborator

Medtronic (Shanghai) Management Co. Ltd.

INDUSTRY

Sponsor Role collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Weijian Huang, MD

Role: PRINCIPAL_INVESTIGATOR

Wenzhou 1st Affliated Hopsital, Wenzhou Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

First Affliated Hospital, Wenzhou Medical University

Wenzhou, Zhejiang, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Weijian Huang, MD

Role: CONTACT

+86138-0669-1086

Lan Su, MD

Role: CONTACT

+86 137-3874-2616

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FirstWenzhouMU216-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Boston Pace Study
NCT05869500 UNKNOWN NA
AI-Guided Left Bundle Branch Area Pacing
NCT07206602 NOT_YET_RECRUITING NA